Wednesday, December 12, 2007

Revance Gets $43.2M In Series C

Mountain View-based Revance Therapeutics has raised $43.2M in a Series C financing, the firm said Tuesday. The investment came from Medicis, which invested $20M in the deal, along with Essex Woodlands Healthcare Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, and Palo Alto Investors. According to the firm, Leerink Swann LLC acted as the sole placement agent for the financing. Revance Therapeutics develops aesthetic medicines based on the botulinum toxin. More information »